← Back to Clinical Trials
Recruiting NCT04806620

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

Trial Parameters

Condition Post-Acute COVID-19 Syndrome
Sponsor Brain Inflammation Collaborative
Study Type OBSERVATIONAL
Phase N/A
Enrollment 10,000
Sex ALL
Min Age 2 Years
Max Age N/A
Start Date 2023-07-05
Completion 2030-06-30
All Conditions
Post-Acute COVID-19 Syndrome ME/CFS Rheumatic Arthritis Juvenile Rheumatoid Arthritis (JRA) Psoriatic Arthritis (PsA) Ankylosing Spondylitis (AS) Autoimmune Encephalitis Celiac Disease Celiac Disease in Children Chronic Lyme Disease Post-treatment Lyme Disease Syndrome Crohn's Disease Dysautonomia Anorexia Nervosa Bulimia Nervosa ARFID Avoidant / Restrictive Food Intake Disorder Ehlers Danlos Syndrome Endometriosis Fibromyalgia (FM) Long COVID Lupus Migraines Mast Cell Activation Syndrome Multiple Sclerosis Myalgic Encephalomyelitis (ME) Myasthenia Gravis, Generalized Myasthenia Gravis in Children Narcolepsy Obsessive Compulsive Disorder (OCD) PANDAS Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) POTS - Postural Orthostatic Tachycardia Syndrome General Anxiety Disorder, Social Anxiety Disorder PTSD - Post Traumatic Stress Disorder Psoriasis Traumatic Brain Injury Tourette's Syndrome Inflammatory Bowel Disease (IBD) Autoimmune Diseases Neurological Diseases or Conditions Psychiatric Disorder Sjogren's Syndrome Ulcerative Colitis and Crohn's Disease

Brief Summary

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. "Healthy" individuals without brain inflammation are also eligible to participate. The digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.

Eligibility Criteria

Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions: * Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME/CFS), and post-acute neuropsychiatric syndrome (PANS/PANDAS). * Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder. * Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions. Inflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis. * Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions. * "Healthy" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to

Related Trials

VIEW ON CLINICALTRIALS.GOV ↗ MORE POST-ACUTE COVID-19 SYNDROME TRIALS